These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38781964)

  • 1. Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus.
    Edwards KR; Schmidt K; Homad LJ; Kher GM; Xu G; Rodrigues KA; Ben-Akiva E; Abbott J; Prlic M; Newell EW; De Rosa SC; Irvine DJ; Pancera M; McGuire AT
    Cell Rep Med; 2024 Jun; 5(6):101587. PubMed ID: 38781964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques.
    Herrman M; Mühe J; Quink C; Wang F
    J Virol; 2016 Feb; 90(3):1222-30. PubMed ID: 26559839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge.
    Malhi H; Homad LJ; Wan YH; Poudel B; Fiala B; Borst AJ; Wang JY; Walkey C; Price J; Wall A; Singh S; Moodie Z; Carter L; Handa S; Correnti CE; Stoddard BL; Veesler D; Pancera M; Olson J; King NP; McGuire AT
    Cell Rep Med; 2022 Jun; 3(6):100658. PubMed ID: 35705092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
    Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
    Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
    Cui X; Snapper CM
    Front Immunol; 2021; 12():734471. PubMed ID: 34691042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to lytic infection proteins in lymphocryptovirus-infected rhesus macaques: a model for humoral immune responses to epstein-barr virus infection.
    Orlova N; Fogg MH; Carville A; Wang F
    Clin Vaccine Immunol; 2011 Sep; 18(9):1427-34. PubMed ID: 21734064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.
    Leskowitz R; Fogg MH; Zhou XY; Kaur A; Silveira EL; Villinger F; Lieberman PM; Wang F; Ertl HC
    J Virol; 2014 May; 88(9):4721-35. PubMed ID: 24522914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice.
    Wei CJ; Bu W; Nguyen LA; Batchelor JD; Kim J; Pittaluga S; Fuller JR; Nguyen H; Chou TH; Cohen JI; Nabel GJ
    Sci Transl Med; 2022 May; 14(643):eabf3685. PubMed ID: 35507671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies against Epstein-Barr virus infection of B cells can protect from oral viral challenge in the rhesus macaque animal model.
    Mühe J; Aye PP; Quink C; Eng JY; Engelman K; Reimann KA; Wang F
    Cell Rep Med; 2021 Jul; 2(7):100352. PubMed ID: 34337567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus.
    Singh S; Homad LJ; Akins NR; Stoffers CM; Lackhar S; Malhi H; Wan YH; Rawlings DJ; McGuire AT
    Cell Rep Med; 2020 Jun; 1(3):. PubMed ID: 32724901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
    Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
    Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge.
    Sashihara J; Hoshino Y; Bowman JJ; Krogmann T; Burbelo PD; Coffield VM; Kamrud K; Cohen JI
    PLoS Pathog; 2011 Oct; 7(10):e1002308. PubMed ID: 22028652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection.
    Ohashi M; Fogg MH; Orlova N; Quink C; Wang F
    PLoS Pathog; 2012 Dec; 8(12):e1003095. PubMed ID: 23300447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ and CD8+ T-cell responses to latent antigen EBNA-1 and lytic antigen BZLF-1 during persistent lymphocryptovirus infection of rhesus macaques.
    Leskowitz RM; Zhou XY; Villinger F; Fogg MH; Kaur A; Lieberman PM; Wang F; Ertl HC
    J Virol; 2013 Aug; 87(15):8351-62. PubMed ID: 23698300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic vaccination against the rhesus lymphocryptovirus EBNA-1 homologue, rhEBNA-1, elicits T cell responses to novel epitopes in rhesus macaques.
    Silveira EL; Fogg MH; Leskowitz RM; Ertl HC; Wiseman RW; O'Connor DH; Lieberman P; Wang F; Villinger F
    J Virol; 2013 Dec; 87(24):13904-10. PubMed ID: 24089556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection.
    Liu C; Li S; Qiao M; Zeng C; Liu X; Tang Y
    Arch Virol; 2024 Jul; 169(8):167. PubMed ID: 39020055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CD8+ T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue.
    Fogg MH; Kaur A; Cho YG; Wang F
    J Virol; 2005 Oct; 79(20):12681-91. PubMed ID: 16188971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
    Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
    Perez EM; Foley J; Tison T; Silva R; Ogembo JG
    Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Neutralizing Antibody Targeting gH Provides Potent Protection against EBV Challenge
    Hong J; Zhong L; Zheng Q; Wu Q; Zha Z; Wei D; Chen H; Zhang W; Zhang S; Huang Y; Chen K; Chen J; Li S; Zeng MS; Zeng YX; Xia N; Zhang X; Xu M; Chen Y
    J Virol; 2022 Apr; 96(8):e0007522. PubMed ID: 35348362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.